- Home
- CYD vs XNCR Comparison
CYD vs XNCR Comparison
Compare CYD & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYD
- XNCR
- Stock Information
- Founded
- CYD 1951
- XNCR 1997
- Country
- CYD Singapore
- XNCR United States
- Employees
- CYD N/A
- XNCR N/A
- Industry
- CYD Industrial Machinery/Components
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- CYD Industrials
- XNCR Health Care
- Exchange
- CYD Nasdaq
- XNCR Nasdaq
- Market Cap
- CYD 609.7M
- XNCR 565.1M
- IPO Year
- CYD 1994
- XNCR 2013
- Fundamental
- Price
- CYD $22.12
- XNCR $8.73
- Analyst Decision
- CYD
- XNCR Buy
- Analyst Count
- CYD 0
- XNCR 7
- Target Price
- CYD N/A
- XNCR $27.50
- AVG Volume (30 Days)
- CYD 192.1K
- XNCR 540.9K
- Earning Date
- CYD 08-08-2025
- XNCR 08-08-2025
- Dividend Yield
- CYD 1.73%
- XNCR N/A
- EPS Growth
- CYD 17.49
- XNCR N/A
- EPS
- CYD 1.12
- XNCR N/A
- Revenue
- CYD $2,621,360,849.00
- XNCR $127,228,000.00
- Revenue This Year
- CYD $6.43
- XNCR N/A
- Revenue Next Year
- CYD $11.20
- XNCR $28.84
- P/E Ratio
- CYD $20.82
- XNCR N/A
- Revenue Growth
- CYD 6.03
- XNCR N/A
- 52 Week Low
- CYD $8.61
- XNCR $7.16
- 52 Week High
- CYD $26.10
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- CYD 44.20
- XNCR 47.62
- Support Level
- CYD $23.00
- XNCR $9.00
- Resistance Level
- CYD $25.65
- XNCR $9.45
- Average True Range (ATR)
- CYD 1.17
- XNCR 0.45
- MACD
- CYD -0.41
- XNCR -0.01
- Stochastic Oscillator
- CYD 10.05
- XNCR 21.76
About CYD China Yuchai International Limited
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International primarily operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.